Having established in vitro the anti‐proliferative activity of midostaurin and other FLT3 inhibitors, we next asked whether midostaurin could disrupt the proliferative activity in in vivo models of wt FLT3‐expressing AML (Figure 4). This evidence concerns the gene FLT3 and acute myeloid leukemia.